Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Core Insights - Marker Therapeutics, Inc. is hosting a virtual event on May 28, 2025, to discuss the cell therapy landscape and the shortcomings of CAR-T therapies, featuring insights from key opinion leaders in the field [1][2]. Company Overview - Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, TX, focusing on next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [5]. - The company was founded at Baylor College of Medicine and has conducted clinical trials with over 200 patients, demonstrating that its autologous and allogeneic MAR-T cell products are well tolerated and show durable clinical responses [5]. Event Details - The virtual event will include a presentation by Dr. Juan Vera on Marker’s MAR-T cell therapy platform, which aims to address the limitations of existing CAR-T therapies [2][3]. - The agenda includes discussions on the shortcomings of CAR-T therapy, overcoming current limitations, and a roundtable discussion featuring renowned experts in the cancer field [3][4]. Expert Panel - The panel will consist of leading experts such as Dr. Helen Heslop, Dr. Malcolm Brenner, Dr. Manali Kamdar, and Dr. Geoffrey Shouse, who will provide insights into the advancements and challenges in the field of immuno-oncology [4].